News

Long-term treatment with benralizumab — sold as Fasenra for a rare type of asthma — safely leads to clinical remission in up to two-thirds of people with eosinophilic granulomatosis with polyangiitis (EGPA), a real-world study shows. “Across a [two]-year period of treatment, we have observed extremely positive outcomes with benralizumab…

Tavneos (avacopan) improved kidney function and reduced the need for the glucocorticoid prednisone in four older patients who had signs of kidney failure due to ANCA-associated vasculitis (AAV), researchers in Canada report. While Tavneos may help patients enter into remission without the harmful side effects of glucocorticoids, “more…

A 64-year-old man with severe granulomatosis with polyangiitis (GPA) saw his condition improve with the use of a triple combination of standard cyclophosphamide and glucocorticoids along with the experimental therapy telitacicept, according to a case report from China. RemeGen’s telitacicept is approved in China under the brand name…

Treatment with Nucala (mepolizumab) for three or more years is safe, and was effective at easing symptoms and reducing the risk of relapse in people with eosinophilic granulomatosis with polyangiitis (EGPA), the most rare type of ANCA-associated vasculitis (AAV), a real-world study in Japan shows. Further, the need…

About half of people with granulomatosis with polyangiitis (GPA) have impairment of a valve in the heart, a study from Poland indicates. This heart valve dysfunction doesn’t cause notable problems for most patients, but a handful may have more severe complications that can require…

A worse physical health-related quality of life (HRQoL) at diagnosis was associated with a higher mortality risk among a group of ANCA-associated vasculitis (AAV) patients in Korea, according to a new report. This risk was particularly noted in people with the AAV types microscopic polyangiitis, or MPA, and granulomatosis…

Certain clotting markers are found at higher levels in the blood of people with ANCA-associated vasculitis (AAV) when their disease is active than when it’s in remission and symptoms ease or disappear, a study finds. Too much clotting may explain why people with active AAV are at increased risk…

In people with ANCA-associated vasculitis (AAV), evaluating kidney function by a test known as the estimated glomerular filtration rate within six months after their diagnosis helps assess their risk of kidney failure, a study shows. The study, “Adding 6-month parameters for the prediction of kidney prognosis…

Tapering immunosuppressive corticosteroids as much as possible during the first year of treatment for ANCA-associated vasculitis (AAV) reduced long-term complications associated with the disorder, an analysis in Japan finds. Recent developments in AAV treatments have led to faster disease remission and fewer relapses in Asian patients, allowing for…

A higher eosinophil count at diagnosis is linked to more severe disease activity in people with microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA), the two most common types of ANCA-associated vasculitis (AAV), a study suggests. Counting eosinophils, white blood cells that usually release enzymes and other molecules in…